HYDRO-SERP "25"
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HYDRO-SERP "25" (HYDRO-SERP "25").
Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis. Reserpine depletes catecholamines in postganglionic sympathetic nerve endings by inhibiting the vesicular monoamine transporter, leading to reduced sympathetic outflow and vasodilation.
| Metabolism | Hydrochlorothiazide is not extensively metabolized; reserpine is extensively metabolized in the liver via CYP450 enzymes. |
| Excretion | Renal (approximately 30-50% as unchanged drug and metabolites), biliary/fecal (approximately 50-70% as metabolites, with enterohepatic recirculation noted for reserpine component). |
| Half-life | Reserpine: terminal elimination half-life 33-45 hours (range 30-60 hours), with clinical context of prolonged autonomic effects lasting days; hydrochlorothiazide: terminal half-life 6-15 hours (mean 10 hours). |
| Protein binding | Reserpine: 95-98% bound to plasma proteins; hydrochlorothiazide: 60-70% bound to albumin. |
| Volume of Distribution | Reserpine: Vd approximately 0.5-0.7 L/kg, indicating extensive tissue distribution and high lipophilicity; hydrochlorothiazide: Vd 0.2-0.4 L/kg, primarily confined to extracellular fluid. |
| Bioavailability | Reserpine: oral bioavailability approximately 50% due to first-pass metabolism; hydrochlorothiazide: oral bioavailability 65-75%. |
| Onset of Action | Reserpine: oral 3-7 days for full antihypertensive effect; hydrochlorothiazide: oral 2 hours (diuresis), 3-4 hours (peak antihypertensive). |
| Duration of Action | Reserpine: oral 1-2 weeks after discontinuation due to irreversible binding to monoamine transporters; hydrochlorothiazide: oral 6-12 hours (diuretic), 12-24 hours (antihypertensive). |
Hydrochlorothiazide 25 mg orally once daily in the morning. Maximum 100 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: 25 mg once daily. GFR 15-29 mL/min: not recommended. GFR <15 mL/min: contraindicated. |
| Liver impairment | Child-Pugh Class A or B: no adjustment. Child-Pugh Class C: use with caution, consider starting at 12.5 mg daily. |
| Pediatric use | Weight-based: 1-2 mg/kg/day orally divided every 12-24 hours, maximum 100 mg/day. |
| Geriatric use | Start at 12.5 mg daily; monitor electrolytes and renal function; may increase to 25 mg daily if needed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HYDRO-SERP "25" (HYDRO-SERP "25").
| Breastfeeding | Reserpine is excreted into breast milk with an M/P ratio of 0.5. Due to the potential for serious adverse reactions in nursing infants, including gastrointestinal disturbances, nasal congestion, and lethargy, breastfeeding is contraindicated during reserpine therapy. |
| Teratogenic Risk | FDA Pregnancy Category D. Use of reserpine in the first trimester is associated with an increased risk of congenital malformations, including neural tube defects and cardiovascular anomalies. In the second and third trimesters, exposure may cause fetal bradycardia, hypothermia, and respiratory depression due to depletion of catecholamines. Chronic use may lead to fetal growth restriction. |
■ FDA Black Box Warning
None
| Serious Effects |
["Anuria","Sulfonamide allergy (hydrochlorothiazide is a sulfonamide)","Known hypersensitivity to hydrochlorothiazide or reserpine","Active peptic ulcer (due to reserpine)","Electroconvulsive therapy (within 7 days, due to reserpine)"]
| Precautions | ["May cause electrolyte imbalance (hypokalemia, hyponatremia)","May exacerbate systemic lupus erythematosus","Reserpine may cause mental depression, peptic ulcer, and nasal congestion","Photosensitivity","Orthostatic hypotension with reserpine"] |
Loading safety data…
| Fetal Monitoring | Maternal: Baseline and periodic monitoring of blood pressure, heart rate, mental status, and gastrointestinal function. Fetal: Ultrasound for growth assessment and amniotic fluid volume; fetal heart rate monitoring during labor for signs of bradycardia. |
| Fertility Effects | Reserpine may impair fertility in both males and females by interfering with hypothalamic-pituitary-gonadal axis. Animal studies have shown reduced spermatogenesis and ovulation. Human data are limited, but reserpine use has been associated with menstrual irregularities and erectile dysfunction. |